4.9/5
( 315+ reviews)
Features Urban ePRO
The study will evaluate the efficacy and safety of obinutuzumab in patients with advanced non-pretreated follicular lymphoma (LF) undergoing treatment with obinutuzumab as part of routine clinical practice, measured by the percentage of patients who relapsed in 24 months following the start of treatment (POD24).
📚
Learning Tools
Enhance your learning experience with interactive features.
🍽️
Food & Dining
Discover recipes and order food from your favorite restaurants.
👶
Parenting Tools
Track and manage your child's development and daily activities.
Screenshots
See the Urban ePRO in Action
Get the App Today
Download on Google Play
Available for Android 8.0 and above